Next Article in Journal
RNAi-Mediated Down-Regulation of Dicer-Like 2 and 4 Changes the Response of ‘Moneymaker’ Tomato to Potato Spindle Tuber Viroid Infection from Tolerance to Lethal Systemic Necrosis, Accompanied by Up-Regulation of miR398, 398a-3p and Production of Excessive Amount of Reactive Oxygen Species
Next Article in Special Issue
Phage Therapy Regulation: From Night to Dawn
Previous Article in Journal
Epidemiology of Norovirus Outbreaks Reported to the Public Health Emergency Event Surveillance System, China, 2014–2017
Previous Article in Special Issue
Towards Inhaled Phage Therapy in Western Europe

Current State of Compassionate Phage Therapy

Unit of Regenerative Medicine, Department of Musculoskeletal Medicine, Service of Plastic, Reconstructive, & Hand Surgery, University Hospital of Lausanne (CHUV), 1066 Epalignes, Switzerland
Swiss Federal Institute of Technology Lausanne (EPFL), 1015 Lausanne, Switzerland
Phage Directory, Atlanta, GA 30303, USA
Yale University, New Haven, CT 06520, USA
Author to whom correspondence should be addressed.
Viruses 2019, 11(4), 343;
Received: 1 March 2019 / Revised: 4 April 2019 / Accepted: 6 April 2019 / Published: 12 April 2019
(This article belongs to the Special Issue Hurdles for Phage Therapy (PT) to Become a Reality)
There is a current unmet medical need for the treatment of antibiotic-resistant infections, and in the absence of approved alternatives, some clinicians are turning to empirical ones, such as phage therapy, for compassionate treatment. Phage therapy is ideal for compassionate use due to its long-standing historical use and publications, apparent lack of adverse effects, and solid support by fundamental research. Increased media coverage and peer-reviewed articles have given rise to a more widespread familiarity with its therapeutic potential. However, compassionate phage therapy (cPT) remains limited to a small number of experimental treatment centers or associated with individual physicians and researchers. It is possible, with the creation of guidelines and a greater central coordination, that cPT could reach more of those in need, starting by increasing the availability of phages. Subsequent steps, particularly production and purification, are difficult to scale, and treatment paradigms stand highly variable between cases, or are frequently not reported. This article serves both to synopsize cPT publications to date and to discuss currently available phage sources for cPT. As the antibiotic resistance crisis continues to grow and the future of phage therapy clinical trials remains undetermined, cPT represents a possibility for bridging the gap between current treatment failures and future approved alternatives. Streamlining the process of cPT will help to ensure high quality, therapeutically-beneficial, and safe treatment. View Full-Text
Keywords: bacteriophage therapy; compassionate use; antibiotic resistance bacteriophage therapy; compassionate use; antibiotic resistance
Show Figures

Figure 1

MDPI and ACS Style

McCallin, S.; Sacher, J.C.; Zheng, J.; Chan, B.K. Current State of Compassionate Phage Therapy. Viruses 2019, 11, 343.

AMA Style

McCallin S, Sacher JC, Zheng J, Chan BK. Current State of Compassionate Phage Therapy. Viruses. 2019; 11(4):343.

Chicago/Turabian Style

McCallin, Shawna, Jessica C. Sacher, Jan Zheng, and Benjamin K. Chan 2019. "Current State of Compassionate Phage Therapy" Viruses 11, no. 4: 343.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop